Regulatory News:
“In 2014, Specialty care sales grew 9.9%1, driven by the acceleration of Somatuline® growth across all geographies, Dysport® solid performance, and the rebound of Decapeptyl® after a particularly difficult year 2013. Moreover, Primary care started to level off thanks to its emerging markets presence.”
Ipsen (Euronext: IPN; ADR: IPSEY) today reported its sales for the fourth quarter and the full year 2014.
Help employers find you! Check out all the jobs and post your resume.
“In 2014, Specialty care sales grew 9.9%1, driven by the acceleration of Somatuline® growth across all geographies, Dysport® solid performance, and the rebound of Decapeptyl® after a particularly difficult year 2013. Moreover, Primary care started to level off thanks to its emerging markets presence.”
Ipsen (Euronext: IPN; ADR: IPSEY) today reported its sales for the fourth quarter and the full year 2014.
Help employers find you! Check out all the jobs and post your resume.
